The research advances in AD pathogenesis and the repeated failures of clinical trials for the anti-amyloid drugs further motivated a focus shift to investigate the role of tau pathology in the AD pathogenesis, also as target for novel drug developments [12]. The gene discussed is MAPT; the disease is Alzheimer disease.